Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News AIM ImmunoTech Inc AIM

Healthcare Biotechnology
AIM ImmunoTech Inc. is an immuno-pharma company. It is focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases. Its flagship products are Ampligen (rintatolimod), a drug of large macromolecular ribonucleic acid (RNA) molecules, and Alferon N Injection (Interferon alfa). Its lead product is an investigational drug called... see more

Recent & Breaking News (NYSEAM:AIM)

AIMIA REPORTS FOURTH QUARTER 2022 RESULTS

Canada NewsWire March 16, 2023

AIMIA DECLARES PREFERRED SHARE DIVIDENDS

Canada NewsWire March 16, 2023

AIM ImmunoTech Announces Publication of New Analysis of the Mechanism of Action of Ampligen as a Potential Prophylactic Therapy Against Ebola Virus Disease

GlobeNewswire March 8, 2023

AIM ImmunoTech Issues Letter to Stockholders

GlobeNewswire March 6, 2023

AIM ImmunoTech Announces Phase 2 Study of Ampligen® for the Treatment of Pancreatic Cancer is Open and Recruiting Patients

GlobeNewswire February 28, 2023

AIM ImmunoTech to Participate in Solve M.E. and The Biotechnology Innovation Organization (BIO) Virtual Event, "Long Covid: What Will It Take To Accelerate Therapeutic Progress?"

GlobeNewswire February 17, 2023

AIM ImmunoTech Enters into Pancreatic Cancer Clinical Research Agreements with AstraZeneca and Erasmus Medical Center

GlobeNewswire January 17, 2023

JTC Team to Host the Virtual Investor 2023 Companies to Watch Event on January 17th, 18th, and 19th

Accesswire January 11, 2023

AIM ImmunoTech Broadens Patent Portfolio with New Netherlands Utility Patent Covering Ampligen® and Other AIM-Developed dsRNA Products to Include Rugged dsRNA for Use in COVID-19 Treatment or Prevention

GlobeNewswire January 9, 2023

AIM ImmunoTech to Present at the 'Virtual Investor 2023 Companies to Watch Event'

GlobeNewswire January 5, 2023

AIM ImmunoTech Appoints Christopher McAleer, Ph.D. as Scientific Officer

GlobeNewswire December 12, 2022

AIM ImmunoTech Reports Positive Safety, Tolerability and Biological Activity Data for Intranasal Ampligen® (Rintatolimod) in Healthy Subjects

GlobeNewswire December 8, 2022

AIM ImmunoTech Announces Abstract Accepted for Poster Presentation at the British Society for Immunology Congress 2022

GlobeNewswire December 2, 2022

AIM ImmunoTech Reports Third Quarter 2022 Financial Results and Provides Corporate Update

GlobeNewswire November 15, 2022

AIM ImmunoTech Announces Presentation of New Data from Roswell Park Comprehensive Cancer Center Evaluating Ampligen® as a Component of a Chemokine-Modulating (CKM) Regimen, with Paclitaxel, for the Treatment of Early-Stage Triple Negative Breast Cancer

GlobeNewswire November 14, 2022

AIM ImmunoTech Announces Corporate Governance Enhancements

Business Wire November 9, 2022

AIM ImmunoTech Shareholders Elect All Three Company Director Nominees at 2022 Annual Meeting

Business Wire November 3, 2022

AIM ImmunoTech Receives Orphan Drug Designation for Ampligen (rintatolimod) for the Treatment of Ebola Virus Disease

GlobeNewswire November 2, 2022

Delaware Court Rules in Favor of AIM ImmunoTech and Declines to Declare Activist Group's Nominations Valid

Business Wire October 31, 2022

AIM ImmunoTech Board Issues Letter to Shareholders

Business Wire October 26, 2022